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Introduction: Among the OMICS technologies, that have emerged in recent years, metabolomics 
has allowed relevant step forwards in clinical research. Several improvements in disease diagnosis 
and clinical management have been permitted, even in neonatology. Among potentially evaluable 
biofluids, breast milk (BM) results are highly interesting, representing a fluid of conjunction between 
mothers newborns, describing their interaction. 
Areas covered: in this review, updating a previous review article, we discuss research article and 
reviews on BM metabolomics and found in MEDLINE using metabolomics, breast milk, neonatal 
nutrition, breastfeeding, human milk composition and preterm neonates as keywords. 
Expert opinion: Our research group has a profound interest in metabolomics research. In 2012, 
we published the first metabolomic analysis on BM samples, reporting interesting data on its 
composition and relevant differences with formula milk (FM), useful to improve FM composition. As 
confirmed by successive studies, such technology can detect the specific BM composition and its 
dependence on several variables, including lactation stage, gestational age, maternal or 
environmental conditions. Moreover, since BM contaminants or drug levels can be detected, 
metabolomics also results useful to determine BM safety. These are only few practical applications 
of BM analysis, which will be reviewed in this paper.  
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● Breastfeeding is beneficial for both newborn and his mother, although BM components and their 
properties are not fully understood; 
● Metabolomics provides a complete and dynamic analysis of BM samples, obtained in a non 
invasive way;  
● Such technology allows a full characterization of BM and determination of its variations over 
lactation stages; 
● Metabolomics allows the comprehension of maternal factors affecting BM composition; 
● The characterization of BM metabolome in each category of newborns allows the comprehension 
of milk variations in more vulnerable patients; 
● Metabolomics can describe the effects of BM components on gut microbiome of breastfed infant; 
● Metabolomics can compare BM, FM and other kinds of milk, allowing the realization of improved 
formulas; 
● Interesting findings are also reported in animal or in vitro models, suggesting ideas for future 
research; 
● BM contaminants, adulterants, drugs or the levels of micronutrients can be detected; 
● Metabolomic analysis can describe the effects of several treatments on milk samples; 
● BM metabolomics can be correlated with several neonatal or infantile outcomes; 
● The contemporary analysis of more biofluids from the same subject can detect the direct effects 
of nutrition on neonatal metabolome; 
● An integrated approach based on the combination of several techniques could be useful;  













Human breast milk (BM) is the ideal food for newborns and infants, highly bioavailable and easy to 
digest. This nourishment is unique: it is a specie-specific biological dynamic fluid which can change 
significantly from one woman to another. Moreover, BM varies constantly during lactation to adapt 
itself to the physiological needs of the developing infant [1,2]. This is also due to the gradual 
maturation of the mammary gland, which depends on the placenta and thus on the progress of the 
pregnancy [3]. World Health organization (WHO) recommends breastfeeding as the best nutrition 
for the growth and development of all infants and as an integral part of the reproductive process 
[4,5]. In addition, maternal BM is the only nutrition “customized” to each neonate; literature data 
report that BM meets the nutritional needs of term newborns, without supplementation, for the first 
6 months of postnatal life. Breastfeeding continuation is then considered optimal for at least 1 and 
up to 2 years or longer, with age-appropriate complementary feeding [6-8].  
These recommendations are also due to the beneficial effects of BM on short- and long-term 
maternal and infant health outcomes [1,4,5,9]. Specifically, lactation has been shown to have 
beneficial effects on maternal glucose metabolism [10-12] and BM is still the most critical factor in 
the protection against infections for both term and preterm newborns [13,14]. Colostrum (i.e., milk 
expressed for the first 5 days after birth) has not only a nutritional role, but also immunological and 
trophic functions. It is involved in the immunological maturation of the intestine and contains a 
great amount of peptides with antihypertensive, antimicrobic and anti-inflammatory properties, 
having a critical role in preventing necrotizing enterocolitis (NEC) and late-onset sepsis and 
retinopathy of prematurity in preterm babies. These components, also present in mature milk (MM, 
defined as milk secreted after the 15th day from birth), support intestinal trophism, induce 
maturation of the immune system, mitigate inflammation, and avoid dysbiosis. In addition, 
epidemiologic evidence has shown several long-term protective effect of breastfeeding against 
metabolic syndromes, obesity and type 2 diabetes in offspring [15-18], while at the same time 
suggesting a role in improving neurodevelopmental outcome of preterm infants [19,20]. 
This benefits are related to the unique “universe” of biological active components present in BM. It 
consists of 88% water and contains 10,000–13,000,000 cells/mL. In addition to the classical 
nutrients (such as proteins, carbohydrates, lipids, vitamins, and minerals), BM contains several 
variable bioactive molecules such as growth factors (GFs), enzymes, hormones, cytokines, 
chemokines, oligosaccharides (HMOs) and antimicrobial compounds. Moreover, nonprotein 
molecules containing nitrogen (creatine, amino acids, nucleotides, polyamines) and nonpolar lipids 
have been described. All these components are necessary for the optimal development of the 
newborn. A complete review of the actual knowledge regarding BM metabolites, especially small 
metabolites (<1500 Da) and their effect on breastfed neonates development can be found in the 










Many factors are recognized to influence BM composition: lactation phase, day moment, GA at 
birth, age of the newborn, gestational pathologies, mother’s nutritional status, geographic 
provenience and metabolic pathways during pregnancy [22,23].  
Thus, BM can modify itself according to neonatal needs during growth and development [24]. 
Moreover, BM components can influence neonatal gut microbiome, allowing the growth of 
beneficial bacterial species instead of pathogens [25]. 
The fact that BM composition can be modified by several factors is also essential to adapt to the 
nutritional needs of premature newborns, which are unique and multifaceted. The BM of mothers 
having delivered preterm has a distinct composition: it is initially high in protein, fat, free amino 
acids, and sodium, but over the first few weeks following delivery these levels decrease. On the 
other hand, the mineral content (including trace minerals) of preterm milk is similar to that of term 
milk, with the following exceptions: Calcium is significantly lower in preterm milk (and does not 
increase over time) whereas Copper and Zinc content are both higher in preterm milk and 
decrease over the time of lactation [26,27].  
To meet the unique nutritional requirements of preterm infants while preserving the benefits of 
breastfeeding, BM should be fortified to allow adequate growth and bone mineralization. 
The fortification of BM with more than one nutritional component is associated with short-term 
improvements in weight gain, linear and head growth. The optimal method for BM fortification 
remains to be determined, and a variety of protocols are currently used in neonatal units. For 
instance, it has been observed that the protein content of BM after standard fortification (which is 
typically based on the customary assumptions on BM composition) fails to meet the recommended 
intake for preterm infants in approximately 50% of cases. Low protein intake has been proven to be 
the primary limiting factor for growth failure in preterm infants.  
However, the protein concentration of preterm BM is variable and decreases with the duration of 
lactation. Recently, good results have been obtained with individual fortification of human milk that 
compensates for the high variability of expressed BM composition, particularly for protein and fat 
content. There are two models of individualization: the “adjustable fortification” based on the 
infant’s metabolic response and the “targeted fortification” based on the analysis of human milk 
and on its fortification in such a way that each infant always receives the amount of needed 
nutrients [28].  
 BM is a complex system, only partially understood and characterized. New and promising 
techniques, such as metabolomics, could allow us to expand our knowledge in this field. 
Metabolomics investigates the whole of products of metabolism in biological liquids, like BM, to 
detect the dynamic interactions among different components of such biological system [29]. 
Thanks to its capacity to describe hundreds of small molecules and determine the characteristic 
signatures of the entire metabolism in biological processes, metabolomics is a most useful 










The three principal analytical techniques applied in metabolomics studies are nuclear magnetic 
resonance (NMR),   gas chromatography coupled to mass spectrometry (GC-MS) and liquid 
chromatography coupled with single-stage mass spectrometry (LC-MS) [31,32].  
Due to the specific advantages and disadvantages of each of these platforms, they result highly 
complementary and the integration of multiple technologies is required for a complete 
characterization of the metabolites in a sample. In metabolomics, the technique of choice depends 
on several factors, such as the study design, the kind of samples, the costs and the expertise of 
the operators.  
NMR, highly automatable and reproducible, is the ideal tool for long-term or large-scale clinical 
metabolomics studies; moreover, it also allows metabolic analysis of living samples and results 
useful to detect sugars, organic acids, and polar compounds. Despite these advantages, NMR is 
less sensitive than LC-MS and GC-MS, with limits of detection about 10-100 times higher; 
however, LC-MS and GC-MS methods can not be used to analyze living samples [31].  
Further details and a complete comparison among such three platforms in metabolomics can be 
found in the very recent review of Emwas and colleagues [31]. 
The identification of specific alterations in metabolomic profiles can improve our knowledge of 
pathophysiological processes. At the same time, it may represent a useful instrument in disease 
diagnosis and therapy monitoring. The application of metabolomics in neonatology offers an 
innovative and promising approach to investigate the complex relationships occurring between 
nutrition and infant’s health. The characterization of BM metabolome and its comparison to formula 
milk (FM) allows understanding how each nutrient affects neonatal metabolism, and offers the 
chance to intervene on the diet composition according to the exact nutritional request of the 
neonate. The complete study of the entire metabolomic spectrum of milk requires the combination 
of different techniques since the metabolites described are quite numerous and require an 
extensive and global study. 
In addition to several well-known BM beneficial effects, current research is pointing out new 
evidence and promising fields of application. I.e., According to a recent study, human BM 
administration in children aged 0–5 years the from 3 days before to  14 days after bone marrow 
transplant would reduce intestinal inflammation (observed through metabolomics analysis of 
stools) and could be a valuable adjunct for patients after bone marrow transplant [33]. 
In this review, we analyze and discuss literature data concerning the BM metabolome, to improve 
the current knowledge on the metabolic variability of the BM through the phases of lactation, its 
variations according to GA at birth and mother gestational pathologies. 
The first application of metabolomics to highlight BM features was performed by our study group 
and published in the article of Cesare Marincola et al. in 2012 [34]. Subsequently, several authors 
described metabolic pathways of BM samples collected from different cohort of mothers at different 










time in a review article by our group, in 2015 evidencing a high BM variability during the first three 
months of lactation, a high dependence on gestational age (GA) at birth and different metabolic 
features comparing colostrum and MM [39]. Moreover, preterm samples seem characterized by 
higher levels of metabolites promoting energy production and cerebral growth, adapting to 
premature newborns needs [40]. 
The aim of this review is summarizing the results of metabolomics studies on BM, updating and 
integrating the review of Cesare-Marincola 2015 [39] and, as in such paper, resuming main results 
and sample characteristics in a detailed table (Table 1).  
For the literature update, we used research articles and reviews found on MEDLINE using 
metabolomics, breast milk, neonatal nutrition, breastfeeding, human milk composition and preterm 
neonates as key words. 
Then we discuss main results of such papers, classified in paragraphs according to the kind of the 
study and the areas of investigation. 
 
2. EXPERIENCES FROM ANIMAL OR CELLULAR MODELS 
 
In BM research, some metabolomics interesting data came from in vitro or animal models. Below, 
we report recent and interesting findings on this topic. 
In weanling rats, metabolomics allowed the investigation of BM or FM effects on gut microbiome 
and plasma metabolome [41], underlining the importance of a combined approach to evaluate the 
correlations between BM and consequent metabolic pathways in breastfed subjects. 
Through the analysis of bovine milk samples, the effects of different dairy procedures on milk 
metabolites were studied. Lipid fraction of organic vs conventional bovine milk result different, 
confirming the promising metabolomics role also in the evaluation of different milk treatments [42].  
In an experimental model of Streptococcus uberis mastitis in dairy cows, milk evidenced a specific 
peptidomic variation in relation to the inflammatory status [43].  
Metabolomic results can be useful to investigate the effects of each component on health outcome. 
Milk fat globule membrane (MFGM) supplementation in BM was showed to improve brain 
development and neurocognitive outcomes in rats [44]; metabolomic variations in pig colostrum, 
depending on pig breeds and parity, could affect piglets' outcome and survival [45].  
A recent study highlighted for the first time the effects of prebiotic bovine milk oligosaccharides 
(BMO) addition in a high-fat (HF) diet-induced obesity in mice; the addiction of BMO seems 
contrast weight gain. Moreover, it could completely prevent intestinal permeability and intestinal 
dysbiosis, increasing the level of beneficial species such as Bifidobacteria spp. and Lactobacilli 
spp. [46].  
The supplementation with sialylated bovine milk oligosaccharides (S-BMO) seem also to improve 










month old undernourished stunted Malawian infants, after a fecal transplant. It was observed that 
S-BMO can determine lean body mass gain, also improving bone morphology, and liver, muscle 
and cerebral metabolism [47].  
In the same research field, Cowardin and co-workers [48] recently colonized young germ-free mice 
with the gut microbiota of a stunted 6-mo-old infant, demonstrating a decreased bone reabsorption, 
osteoclastogenesis, increased femoral trabecular bone and cortical thickness after the 
supplementation with some purified S-BMO, through a gut microbiota–bone axis interaction [48]. 
Although preliminary, these findings suggest an interaction occurring between S-BMO and gut 
microbiota, potentially improving future therapeutic strategies for neonatal development and 
resulting promising in children undernutrition, that represents a global health problem. 
The effects of HMOs on neonatal brain development have been recently evaluated in a preterm-pig 
model by Obelitz-Ryom and colleagues [49]. At 3 weeks of age, after the supplementation with 
oligosaccharide-enriched whey with sialyllactose, preterm pigs showed improved functional brain 
performances and spatial cognition, increased expression of myelination genes of sialic acid 
metabolism in the hippocampus and ganglioside biosynthesis. Thus, if these data would be 
confirmed, sialic acid supplementation in neonatal FM could support preterm brain development 
[49].  
The role of HMOs in stimulating gut maturation, acting as prebiotics and immunomodulators, and 
potentially reducing the occurrence of NEC led to the consideration that their supplementation 
could be useful in preterm neonates. However, some animal models evidenced that the efficacy of 
HMOs supplementation requires further investigation, even taking into account the timing of 
supplementation, the gut immaturity and feeding intolerance [50]. 
Metabolomics also result useful to evaluate the effects of BM compounds on bacterial growth. 
According to recent in vitro findings, the growth of Lactobacillus reuteri DSM 17938 is higher in BM 
than in FM. BM promotes LR 17938-associated metabolites, as reported by the up-regulation of 
specific metabolites, enhancing its growth and physiological effects [51].  
Capillary electrophoresis and time-of-flight mass spectrometry (CETOFMS) has been also applied 
to analyze the network occurring between the intestinal microbiome and the host metabolites in 
mice, helping in the characterization of gut metabolism [52]. 
The high number of experiments and studies focusing on metabolomic BM analysis underline the 
importance of such models to describe BM micronutrients, the effects of BM or FM 











3. MATERNAL FACTORS 
 
The influence on maternal factors on BM production are widely investigated.  
The application of metabolomics gave interesting results on maternal urine, pointing out 
metabolites associated with maternal possibility to breastfed and an adequate BM production [53].  
Very promising results, in this field, can be obtained by the application of metabolomics on BM 
samples.  
Maternal ethnicity and its influence on BM metabolome was also investigated by Gay et al. [23], 
analyzing n=109 BM samples, at one month postpartum, from five countries (Australia n=29, Japan 
n=12, USA n=18, Norway n=40, and South Africa n=10). Samples underwent 1H-NMR.  
Among n=28 identified metabolites, sugars (fucose, glucose, lactose), amino acids (alanine, 
glutamine, glutamate, glycine, isoleucine, leucine, valine), choline and energy metabolites 
(acetone, citrate, creatine, creatine phosphate, creatinine, lactate, 2-oxoglutarate, pyruvate, 
succinate) were detected. The highest variation occurred among South African samples, compared 
with Norwegian or Australian mothers. In detail, three clusters of milk separation were shown: 
Black, Caucasian and Asian.  
In South African mothers, lactose, 2-oxoglutarate, citrate, creatine, creatine-phosphate, creatinine, 
betaine and glycerol-phosphocholine showed higher levels than Norwegian (and, except for 2-
oxoglurate and glycerol-phosphocholine, than Australian samples).  
Glucose, fucose content and other energy metabolites (i.e., succinate) did not show significant 
regional variations.  
Glutamine resulted significantly lower in Norwegian versus US women. In Japanese women, 
significantly higher levels of pyruvate and lactate than Norwegian women were detected. Methanol 
was significantly lower in Norway BM samples than other countries. 
Lactate differentiated Asian samples; 2-Oxoglutarate, creatine, creatine phosphate, creatinine, 
betaine and glycerophosphocholine were higher while valine was lower in Black population. 
Glutamate, glutamine, glucose, and phosphocholine characterized Caucasian samples, which 
resulted less rich in lactate and fucose than Asian samples.  
Differences in these milk metabolites occurred according to geographic variations. According to 
these authors, BM is influenced by regional maternal diet, health status, genetics and 
breastfeeding practices [23].  
Grapov and colleagues [54] pointed out interesting results analyzing BM samples (1-3 days of 
lactation, colostrum) in mothers affected by gestational diabetes mellitus (GDM) (n=6) and 
comparing it to n = 12 healthy mothers. High-resolution, high-mass accuracy liquid 
chromatography tandem mass spectrometry LC−MS detected n=601 proteins; n=27 resulted the 
best indicators of GDM. Among these, n=10 proteins were statistically significantly different in 










regarding proteins with nutritional and immunity roles and potentially influencing neonatal outcome 
[54].  
Finally, we present a very interesting report evaluating breastfeeding safety and BM metabolic 
composition during acute kidney injury (AKI) [55] in n=1 mother aged 35 year who, due to the 
occurrence of a postpartum hemorrhage, underwent a computer tomography (CT) and 
administration of a contrast dye on the 1st day postpartum, showing AKI. This is the first study 
investigating such topic; guidelines regarding breastfeeding recommendations in AKI or chronic 
kidney disease (CKD) are lacking. 1H-NMR was applied to compare BM samples from n=1 AKI 
lactating mother to n=1 healthy control. AKI mother started hemodialysis (HD) on day 4 
postpartum. BM samples were obtained on day 1 and 4 (before HD in AKI mother) and on day 4 in 
healthy mother.  
BM from AKI mother on day 4 showed lower levels of alanine, glutamine, glutamate, glycine, 
valine, glucose, citrate, glycerol, phosphocholine, and valerate similar levels of lactose and more 
maltose, creatinine, hippurate, creatine, creatine phosphate, acetone, choline and pyruvate than 
healthy control. No difference occurred in fatty acids (FAs). Moreover, AKI milk on day 4 showed a 
higher Ph. 
Finally, authors underline that iodinaxol level significantly decreased from day one to day 4 
postpartum (55 to 28 mg/mL). From these data, it can be deduced that AKI can change BM 
composition, especially reducing amino acid concentrations and increasing catabolites, not 
affecting major nutrients content (lactose and lipids).  
Moreover, dye radio contrast for CT does not significantly accumulate in BM (only low levels), thus 
breastfeeding seems safe also after a procedure involving CT dye contrast maternal administration 
even in case of AKI. Breastfed neonate exposure was low even in case of maternal impaired renal 
excretion. These interesting results should be proved on larger cohorts [55].  
 
4. BREAST MILK OLIGOSACCHARIDES AND SECRETOR STATUS 
 
HMOs are a complex family of soluble unconjugated glycans. Such structures are highly 
represented in BM and show a higher inter-individual variability; moreover, they exert positive 
effects on neonate and lactating mother.  
HMOs can shape neonatal gut microbiome and metabolome in a cross-feeding mechanism, 
promoting the growth of commensal species, can modulate neonatal intestinal mucosa and its 
maturation and also improve immune system, protecting against infections [40,56].  
Metabolomic investigation of HMOs will improve the characterization of such structures, the factors 
influencing their variability and, due to their absence in bovine-derived formulations, the potential 










BM analysis can also allow the distinction of lactating mothers in Secretors (Se+) and non 
Secretors (Se-), depending on maternal expression of alpha-1-2-fucosyltransferase (codified by 
secretor gene, FUT2) and alpha-1-3-4-fucosyltransferase (codified by Lewis gene, FUT3); thus, 
maternal phenotypes can be: Se+/Le+, Se+/Le−, Se−/Le+, and Se-/Le−, determining significant 
differences in BM composition (especially HMOs) [54,57].  
Metabolomics can be applied to evaluate HMOs content in BM and to obtain information regarding 
maternal secretor status. In a recent study of our research group [57], n=58 BM samples of 
colostrum (on the 4th day of lactation) from n=58 full-term delivering mothers were evaluated with 
1H-NMR. Then, three subgroups were performed, according to neonatal BW: n=48 appropriate for 
GA (AGA) neonates, n=2 large for GA (LGA), n=10 small for GA (SGA).  
From the analysis, two groups were clearly distinguished based on their HMOs content. One group 
of samples contained more α1,3/4-linked fucosyl-oligosaccharides, with fucose linked only by α1,3 
or α1,4 glycosidic bonds (while α1,2 fucosyloligosaccharides  were lacking); In the second group 
α1,2 fucosyloligosaccharide units were abundant: these two groups corresponded to Se- and Se+ 
groups respectively. Moreover, the study does not report significant differences in HMOs according 
to GA, birth weight (BW), delivery mode and gender [57]. 
The proportion of women classified as secretors was also influenced by ethnicity and ranged from 
65% in Gambia and Ethiopia to 98% in Peru. The percentage of secretors in the cohort in Peru 
(98%) was also higher than Ghana and Washington, USA (68%) but similar to the cohort in 
California, USA (95%) [58]. 
A recent study explored the influence of maternal geographic provenience and mode of delivery on 
BM components, through nuclear magnetic resonance spectroscopy (1H-NMR), also evaluating the 
modulation occurring on BM microbiome. N=79 healthy lactating mothers from Finland (n=20), 
Spain (n=20), South Africa (n=19), and China (n=20) were enrolled [25].  
Then, they were classified depending on delivery mode: vaginal delivery (n= 10 for each country) 
or caesarean section (n = 10 for China, Finland, and Spain; n = 9 for South Africa).  
A global number of n=68 different metabolites was detected in MM, at one month of lactation. 
Among these, n=23 were amino acids, n=18 sugars, n=10 lipids and FAs metabolites, n=7 energy 
related metabolites and the other were vitamins or nucleic acids, microbial metabolites or food 
additives. Metabolomic results were highly influenced by geographical provenience. Variating 
levels of galactose, lacto-N-fucopentaose III (LNFP III), lacto-N-fucopentaose I (LNFP I) and 2’-
fucosyllactose (2’FL), 3’-fucosyllactose (3’ FL), lacto-N-difucohexaose II (LNDFH II), , 2-
hydroxybutyrate, 3-hydroxybutyrate, proline, N-acetyl lysine, methyl-histidine, dimethylamine, 
kynurenine, urea, creatine and creatine phosphate, formate, lactate, acetate, phosphocholine, 
acetylcholine, low density lipoproteins (LDL), very low density lipoproteins (VLDL), ethanolamine, 










Among the interesting findings of such study, the authors underline that Chinese mothers showed 
significantly higher levels of 3’FL and LNFP III instead Finland samples.  
LNFP I was higher in Finland mothers, 2’FL, Short-chain fatty acids (SCFAs), acetate and formate 
in Spain samples, 3’FL and LNFP III in South Africa and China, respectively. LDL and VLDL were 
significantly higher in Spain and Finland samples. 
Moreover, delivery mode greatly influences BM metabolome. N=6 metabolites showed statistically 
different levels in mothers undergone vaginal delivery. Among these mothers, higher levels of 3-
hydroxybutyrate and LNFP III and a lower content of butyrate, ethanolamine, proline and urea were 
reported. 
Interestingly, it was also observed that the effect played by cesarean section is modulated by 
geographical location. Finally, according to these data, BM metabolome highly influences microbial 
communities, through several interaction patterns. Such study highlights interesting results; 
Proteobacteria spp., Actinobacteria spp., and Bacilli spp. seem mostly influenced by BM 
metabolome.  
The results of these studies may improve personalized strategies in neonatal nutrition, also 
regarding bioactive components [25]. 
 
5. BREAST MILK CHARACTERIZATION 
 
5.1 Factors affecting breast milk composition 
 
5.1.1 Breast milk relation with prematurity and lactation stage 
 
Metabolomic analysis of BM from mothers delivering pre-term provides many information regarding 
the composition of BM, explaining how it modifies itself to satisfy premature newborn’s necessities 
or explaining potential nutritional deficiencies. This knowledge could improve a personalized 
nutrition.  
The study of Perrone and co-workers [59] evaluated BM differences between full-term and pre-
term delivering mothers and the modifications of such metabolic pathways during lactation.  
Through 1H-NMR, a total of n=30 samples (n=18 mothers) were analyzed. Among them, n=12 
delivered full-term (n=12 samples collected at 4-7 days of lactation) and n=6 delivered pre-term 
(29-31 w of GA. N=3 samples from each mother, at 1-3 w of lactation).  
The two categories were characterized by two different metabolic profiles; in detail, lactose (4.46 
ppm) and HMOs, especially those fucosylated, such as fucose (1.23 ppm), N-acetyl-neuraminic 











Moreover, although BM metabolome varies during lactation, it was shown that at three weeks of 
post-natal age it is not equal to full-term samples, showing higher levels of lactose and HMOs [59].  
Metabolomics changes over lactation were also evaluated on a single-patient based study [5]. 1H-
NMR analysis was performed on n=15 BM samples collected from the same mother (n=1) twice a 
day on the days 9, 12, 24, 31, 60, 85, 86 and 87 of lactation. The results showed a clear separation 
between the samples collected in the early lactation (9-24 days) and late lactation (31-87 days); 
the changes could be related to different neonatal needs during growth. 
The late stage was characterized by an increase in lactose, choline, alanine, glutamate, glutamine, 
butyrate and formate levels and a reduction in citrate, phosphocholine, glycerophosphocholine and 
N-acetylglucosamine [60].  
In a cohort of Chinese women, changes in BM metabolome across lactation stages were detected 
through high-performance liquid chromatography–quadrupole-time of flight mass 
spectrometry (HPLC-QTOFMS) and analyzed according to maternal diet. By Li and co-workers 
[61], samples were collected from n=30 mothers at days 1 (colostrum), 14 days (transition milk-
TM) and 42 (MM) post-partum.  
As result, n=84 metabolites were measured in the three lactation phases. Among them, n=12 were 
fatty acyls, n=15 glycerolipids, n=23 glycerophospholipids, n=7 sphingolipids, n=7 vitamins, n=5 
nucleotides-related metabolites, n=2 amino acids, n=1 amino acid metabolite, n=9 dipeptides, n=1 
steroid hormones, n=1 energy-related metabolite and n=1 amine. 
Samples belonging to the three lactation stages were clearly different when analyzed according to 
metabolomics. As demonstrated, metabolites’ variations did not depend on maternal dietary intake. 
Moreover, some findings resulted quite different from the trends demonstrated in western 
populations, underlining the role of metabolomics also in revealing geographic or maternal genetic 
predisposition.    
In detail, glycyl-valine, histidinyl-threonine, lysyl-threonine, threoninyl-tyrosine, tyrosyl-glutamine, 
tyrosyl-serine, valylvaline, valyl-alanine, histidinyl-histidine, tryptophan, histidine, C10:0, C11:0, 
C14:0, C16:1n-7, C17:0, C18:1n-9, C18:2n-6, prostaglandin E3, octadecanamide, CE (15:1), CE 
(14:0), monoglyceride (15:0), diacylglycerols (14:0/20:4n-6, 14:0/24:1n-9, 14:1n-5/18:3n-3, 
15:0/20:1n-9, 15:0/20:2n-6, 18:0/18:1n-9, 18:4n-3/18:4n-3, 20:0/24:1n-9, 24:0/15:0, 18:3n-3/18:3n-
3, 15:0/16:1n-7 and 14:0/14:1n-5),  triacylglycerols (15:0/14:0/15:0 and 16:0/14:0/16:0), 
lysophosphatidylcholines (18:2n-6 and 18:4n-3), lysophosphatidyl-ethanolamines  (20:2n-6, 15:0), 
phosphatidylcholine (18:0/18:2n-6), phosphatidylethanolamines (20:5n-3/16:0, 18:2n-6/14:1n-5, 
18:1n-9/24:1n-9, 18:4n- 3/18:4n-3 and 16:1n-7/18:0), phosphatidylserines (14:1n-5/18:3n-3 and 
14:0/18:1n-9), phosphatidic acid  (15:0/14:0), phosphatidylglycerophosphate (18:1n-9/18:2n-6), 
sphingosine, phytosphingosine, sphinganine, ceramide-Cer (d18:0/24:0), Cer (d18:0/22:0), 
glucosylceramide (d18:1/12:0), SM (d18:0/18:0), 6-succinoaminopurine, deoxyuridine, 










vitamin D3, 25- hydroxyvitamin D2-25-glucuronide, vitamin D2, biotin, 11β- hydroxyprogesterone, 
cis-Aconitic acid and spermidine increased with BM maturation. 
On the contrary, C14:1n-5, lysophosphatidylcholines (22:6n-3, 16:0 and 22:5n-3), 
lysophosphatidyl-ethanolamines (20:4n-6, 20:3n-6 and 22:0), phosphatidylethanolamines  
(14:0/14:1n-5 and 15:0/14:1n-5), phosphatidic acid (14:1n-5/22:6n- 3), retinoyl β-Glucuronide and 
γ-tocopherol were more abundant in colostrum  [61]. 
Sundekilde et al. [62], firstly investigated and compared metabolic profiles of BM samples collected 
from pre-term and full-term delivering mothers, according to GA at delivery and lactation phase. 
According to their 1H-NMR results, BM for pre-term newborns is significantly different from full-term 
(depending on GA) and BM metabolome varies across lactation. Changes determine a realignment 
of pre-term samples to full-term after 5-7 weeks, independently from GA at birth.  
Samples were constituted by colostrum, < 5 days post-partum (n=5), TM, 6 days-2 w post-partum 
(n=4) and MM, > 2 w (n=21). A total of n=92 samples were analyzed according to lactation phase; 
Samples were collected from n=45 mothers, n=30 delivering full-term and n=15 delivering pre-term 
(<37 w).  Several metabolic differences occurred among colostrum, TM and MM.  
In colostrum of full-term delivering mothers higher levels of valine, leucine, betaine, and creatinine 
were found, instead of MM. Glutamate, caprylate, and caprate were higher full-term MM than 
colostrum. In pre-term colostrum, increased levels of oligosaccharides, citrate and creatinine were 
found. 
Levels of caprylate, caprate, valine, leucine, butyrate, alanine, glutamate, pantothenate 3-FL, lacto-
N-difucohexaose I (LNDFH I) and lactic acid increased across lactation.  
Levels of fucosylated oligosaccharides, fucose, N-acetylneuraminic acid, N-acetylglucosamine, 
valine, leucine, pantothenate, citric acid, lactic acid, choline, betaine ,creatinine fucosyl moieties, 
N-acetylneuraminic acid, N-acetylglucosamine, 3’-sialyllactose (3’SL), 6’-sialyllactose (6’SL) and 
2’FL were higher in colostrum and decreased during milk maturation.  
Most discriminating metabolites between full-term and pre-term BM samples were carnitine, 
caprylate, caprate, pantothenate, urea, lactose, HMOs, citrate, phosphocholine, choline and 
formate.  
Citrate, lactose, phosphocholine, fucosyl moieties, N-acetylneuraminic acid, N-acetylglucosamine, 
3’SL, 6’SL, LNDFH I, glutamate, citric acid, phosphocholine, choline and formic acid were higher in 
pre-term milk samples, while carnitine, caprylate, caprate, pantothenate, beta-hydroxybutyrate and 
urea were higher in full-term samples [62].  
A comparison between dynamic changes of BM composition during the first month of lactation in 
full-term and pre-term samples was also performed by Spevacek and colleagues [20].  1H-NMR 
was applied to investigate samples of colostrum (day 0–5 of lactation), TM (day 14), and MM (day 










From this analysis, n=69 metabolites were detected. In detail, n=15 were sugars, n=23 amino 
acids and derivatives, n=11 energy-related metabolites, n=10 fatty acid–associated metabolites, 
n=3 nucleotides, n=2 vitamins, and n=5 bacteria-related metabolites.  
Colostrum and MM showed a different clusterization. Some metabolites were higher in MM, 
pointing out an increasing trend during lactation. 
Regarding sugars, most HMOs decreased during lactation. Total HMOs and neutral HMOs, 2’-FL, 
3’-galactosyllactose (3’-GSL), 3’-SL, 6’-SL, fucose, LNFP III and Lacto-N-neotetraose (LnNT) 
showed higher levels in full-term colostrum. LNFPII and lactose resulted higher in preterm MM than 
colostrum; 3-FL, glucose, lactose were higher in full-term MM. Moreover, in this sample, N=10 full-
term delivering and n=10 preterm delivering mothers resulted Se+. 
Among aminoacids, alanine was higher in preterm MM. 2-Aminobutyrate, alanine, carnitine, 
glutamate, glutamine, histidine, urea and valine were higher in full-term MM, while acetylcarnitine, 
betaine, isoleucine, lysine and taurine were higher in full-term colostrum.  
Also FAs associated metabolites showed interesting trends; azelate, butyrate, caprylate, Glycero-
3-phosphocholine were higher in preterm MM, decreasing during lactation.  
Butyrate, azelate, caprate, caprylate, ethanolamine, glycero-3-phosphocholine were higher in full-
term MM, while choline and myo-Inositol were higher in full-term colostrum. 
Regarding energy-related metabolites, acetone, creatinine and creatine phosphate resulted higher 
in full-term MM; 2-Oxoglutarate, creatine, fumarate, lactate and pyruvate were higher in full-term 
colostrum. 2-oxoglutarate, acetone, lactate and pyruvate were higher in preterm MM. 
Among nucleotides, adenosine monophosphate (AMP) was higher in full-term mature milk and 
hypoxanthine was higher in full-term colostrum.  
Investigating bacteria related metabolites, it was shown that acetoin increased in preterm MM, 
dimethyl-sulfone increased in full-term MM and was lower in preterm MM while hyppurate and 
methanol were higher in full-term colostrum and lower in preterm colostrum. 
As result, it can be concluded that BM metabolites vary during the first month of lactation and the 
highest variability has b en shown in pre-term samples [20].  
The interesting study of Andreas et al. [63], performed a combined multiplatform approach, using 
HPLC-MS, LC-MS, GC-MS, capillary electrophoresis‐mass spectrometry (CE-MS) and 1H-NMR to 
evaluate n=70 BM samples. They were collected from n=57 lactating mothers delivering full-term. 
Sampling occurred between 2-80 days of lactation. Globally, n=710 metabolites were identified and 
compared during three time intervals: 1–5 days, 6–10 days and >10 days of lactation. 
Most variable metabolites during lactation were lactose, fucose, di- and triacylglycerols, 
aminoacids and short and medium chain FAs, since a gradual increase occurred during lactation. 
These metabolites are involved in immunological, neurological, and gastrointestinal neonatal 










On the contrary, several HMOs, phosphocholines citrate and pyruvate decreased during lactation.  
It is interesting to underline that BM maturation depends on neonatal needs; during lactation, it 
increase its energy content, lipids and carbohydrates. Moreover, maternal factors affecting BM 
composition should be fully clarified [63]. 
In a recent study, Bzikowska-Jura and co-workers [64] investigated FAs levels in BM, determining 
omega-3 FA content in relation to maternal current dietary intake.  N=32 samples from n=32 
women during the first month of lactation were analyzed with GC-MS. They all assumed adequate 
levels of foods containing omega-3 FAs. 
As result, current dietary intake of omega-3 FAs was not significantly correlated with BM content, 
while their habitual intake could influence BM levels. Nutritional habits in the three months prior 
delivery mainly affect BM [64]. 
In a preliminary study, the research group of Cagliari and Turin performed a comparative study 
evaluating BM metabolome in two categories of pre-term samples (extremely preterm: 23–28 
weeks of GA vs moderate preterm: 32–34 weeks). By comparing colostrum, TM and MM, 
metabolic variations were more evident in the first phases of lactation than in MM. In detail, in 
these preliminary data, variations in colostrum mostly regarded choline and derivatives 
metabolites; this is not a surprising result, because choline is a component of cerebral membranes 
and its high level could be related protect and promote the development of our most important 
organ: the brain [65]. 
An interesting study evaluated the effects of BM composition at 1 and 4 months of lactation on 
infant lipid and amino acids serum metabolism. N=196 dyads of mothers and newborns were 
enrolled [66]. 
BM was analyzed with GC-MS for macronutrients and FA content. Phospholipids, acylcarnitines, 
and amino acids were then analyzed in serum samples collected from infants at 4 month of age. 
As result, the authors observed that BM components evaluated in this study have a small impact 
on infants’ serum metabolites. Lyso-phosphatidylcholine (LPC) in serum correlates with BM FAs 
and protein content, esp cially LPC 14:0 (previously associated to growth improvement and 
obesity risk increase) [66]. This is an example of a complementary approach (simultaneous BM 
and serum metabolome) to evaluate the effects of nutrition on neonatal metabolic status. 
In conclusion, these findings point out a great variability of BM metabolites during different phases 
of lactation and according to neonatal GA, probably meeting the specific requirements of each 
newborn. It is not easy to detect specific metabolites increasing or decreasing in each of the 
examined categories and characterizing every phase of lactation, due to the lack of a precise 
standardization among the groups, regarding GA, ethnicity, detection methods and other potential 
confounding factors. However, trying to summarize the mentioned studies, we could state that 
preterm milk samples seems to contain higher levels of lactose, some HMOs (especially fucose, N-










creatinine, phosphocholine, choline, glutamate, citric acid, and formic acid. In preterm MM, the 
increase in LNFPII, lactose, alanine, zelate, butyrate, caprylate, glycero-3-phosphocholine, 
oxoglutarate, acetone, lactate, and pyruvate seems significant, even if all the exact consequences 
on the outcome of premature neonates are not currently exploited. In our opinion, such findings 
highly encourage future studies and research in this direction. 
 
5.1.2 Breast milk and multiple pregnancies 
 
A recent investigation performed by our study group investigated BM composition in multiple 
pregnancies [67], representing about 3% of all pregnancies. It is well known that multiples often 
show lower GA and BW than singletons, resulting more vulnerable to several diseases.  
BM samples from mothers of n=19 couples of twins and n=5 triplets (GA < 33 weeks [w] and BW < 
1500 g in at least one neonate) were analyzed and compared to a control group of n=28 singletons 
(GA ≤28 w).  
Our sample of multiples was composed by n=51 neonates (n=25 males and n=26 females); 
Among n=28 singletons, n=13 were males, n=15 females. BM sampling was performed between 
the 1st and the 20th w of postnatal life.  The total pool of samples from multiples was composed by 
n=103 samples, weekly obtained to detect variation during lactation.   
As result, at GA ≤ 28 weeks, it was detected a significantly higher protein content in BM for 
multiples than singletons (1.53 vs 1.29 g per 100 ml), while lactose content was significantly higher 
in BM for singletons (6.72 vs 6.34 g per 100 ml) [67]. Lactose acts as an osmotic agent to draw 
additional fluid into milk secretory vesicles and in turn could increase milk yield in case of 
breastfeeding challenge as it is the case in multiple pregnancies [68]. 
GA was the factor mostly influencing BM protein content: in fact, a significant inverse correlation 
occurred between the weeks of corrected GA and proteins. Regarding other components, no 
significant modification was detected over time [67].  
To the best of our knowl dge, BM metabolites in mothers delivering multiples has not been 
adequately investigated. In literature, we found a single old study measuring proteins, lactose, and 
FAs content in BM samples collected from eight women breastfeeding twins and one woman 
breastfeeding a triplet [69].  
The higher protein content that our group found in BM from mothers delivering preterm multiples 
could face the needs of such vulnerable category, promoting and sustaining growth and organ 
development. These findings could help in the improvement of nutritional strategies and BM 
individualized fortification. 
A very recently published Spanish survey investigates several maternal and neonatal variables 
influencing breastfeeding length in a large cohort of very low birth weight (VLBW) neonates, 










in-hospital maternal BM feeding, could help in the identification of practices that might be improved 
to avoid early breastfeeding cessation, especially in preterm multiples [70]. 
 
5.2 Recent studies investigating breast milk bioactive components 
 
5.2.1 Proresolution activity 
 
BM contains significant levels of specialized pro-resolving mediators (SRM) involved in host 
defense and anti-inflammation.   Twenty bioactive compounds (e.g. resolvins, protectins, maresins, 
lipoxins and prostanoids) that belong to lipoxygenase (LOX) and cyclooxygenase (COX) pathways 
were detected in MM from a small sample of four healthy donors. In addition, the results showed 
higher levels of proinflammatory mediators (leukotriene B4-LTB4 and prostanoids) and lower levels 
of SPM in BM from mother with mastitis [71]. 
 
5.2.2 Antiviral activity 
 
The possible presence of maternal viruses in BM can determine the transmission to breastfed 
neonates. I.e., maternal Cytomegalovirus (CMV) can undergo periodical reactivations, even in 
case of maternal immunity. This BM-acquired infection can lead to a severe disease, especially in 
premature newborns.  
According to recent data, metabolomics analysis of amniotic fluid (AF) and maternal urines seems 
very useful in the description of neonatal susceptibility to CMV infection and providing information 
regarding the transmission and the severity of disease [72-74].  
In the next future, metabolomics BM analysis could improve our knowledge in the field.  
 
5.2.3 Endogenous mediators  
 
Endocannabinoids and related compounds (endocannabinoid metabolome, ECM) represent 
endogenous mediators originating from long-chain PUFAs and have been detected in BM, as 
confirmed by a recent study of Gaitan et al [24].  
The mechanisms of action and the role of BM ECM are not fully understood; according to a recent 
data, the mediator arachidonoylglycerol seem modulate the type 1 cannabinoid receptor in 
neonatal brain; moreover, bioactive BM constituents may also play a role in infant health and 
development. Here, it could influence the suckling response during lactation. Samples from n=24 
lactating mothers were collected and analyzed with LC-MS. ECM was evaluated in TM and MM, to 










As principal results, variable levels of arachidonoylethanolamine, palmitoylethanolamine, 
oleoylethanolamine, docosahexaenoylethanolamine, eicoapentaenoylethanolamine, 
eicosenoylethanolamine, arachidonoylglycerol, palmitoyglycerol, oleoylglycerol, 
docosahexaenoylglycerol, eicosapentaenoylglycerol, eiconenooylglycerol, arachidonic acid, 
docosahexaenoic acid, and eicosapentaenoic acid were reported. Docosahexaenoylglycerol 
(DHEA) showed significantly different levels between the two stages of lactation (higher in TM) 
[24].  
 
5.3 Breast milk compared with other milk sources, formula milk and bovine samples 
 
To better understand the right fit between milk components and infant needs it is important to know 
the specific lipids and protein requirements of newborns and children. Fat intake in infants, which is 
high during the breastfeeding period, can gradually decrease in the second half of the first year of 
life, from the start of the complementary feeding period up to three years of age: 40 % of total 
dietary energy in the 6 to 12 months period and 35 to 40% in the 2nd and 3rd year of life. Fat intakes 
below 25% of total dietary energy have been associated with low vitamin levels in some young 
children. The concept of protein requirement includes both total Nitrogen and indispensable amino 
acid requirements. The quantity and usage of indispensable amino acids is considered to be an 
indicator of the dietary protein quality, which is usually assessed using the Protein Digestibility 
Corrected Amino Acid Score (PD-CAAS). For infants, children and adolescents, the 
WHO/FAO/UNU (2007) estimated that the protein requirements from six months to adulthood were 
derived factorially as the sum of requirements for maintenance and growth corrected for efficiency 
of protein use. An average maintenance value of 0.66 g protein/kg body weight per day was 
applied. Average daily needs for dietary protein for growth were estimated from average daily rates 
of protein deposition, calculated from studies on whole-body potassium deposition, and from an 
efficiency of use of dietary protein for growth of 58%. The PRI was estimated based on the 
average requirement plus 1.96 SD using a combined SD for growth and maintenance [75]. 
Metabolomics analysis of BM, FM and bovine samples may provide interesting findings, as 
reported by several studies, pointing out a higher interindividual variability and changes occurring 
according to several partially known factors [34].  
Recent studies evaluated this topic. Scano and co-workers [76] compared n=31 BM samples 
collected between 3-26 w of lactation (from full-term delivering mothers) to eight different kinds of 
FM (n=31 samples; among these, n=17 FM for infants aged 0-6 months and n=14 > 6 months) 
through gas chromatography-mass spectrometry (GC–MS). 
As result, metabolites found only in FM were orotic acid and isomaltulose 189.8 mg/dL. Malic acid, 
sugars (glucose 122.8 mg/dL, fructose and galactose) and mannitol 27.6 mg/dL were higher in 










acid 82.7 mg/dL, glycine, and pyroglutamic acid 47.9 mg/dL), urea, and inositols (myo-inositol 
46.1mg/dL and scylloinositol). According to thesa data, metabolome of FM samples is highly 
different from BM and varies according to the kind of analyzed formula, while no significant 
differences occurred between first infant formulas and follow-up formulas [76].  
Lopes et al. [77] focused the attention on lipid profile of BM vs FM, evaluating it with 1H-NMR. 
N=12 commercial FM samples and n=10 BM samples from different mothers were compared.  
It was pointed out that FM shows a significantly lower content of saturated fatty acids (SFAs), 
higher content of unsaturated FAs (UFAs, 38.20% vs 30.59%) and a comparable polyunsaturated 
fatty acid (PUFA 9.92% vs 17.96%) level instead of BM. BM samples were characterized by a 
higher content of SFAs in the sn-2 position (26.03% vs 2.93%) and PUFAs in the sn-1,3 position 
(15.35% vs 3.94%) instead of FM. On the contrary, FM showed SFAs esterified mainly in the sn-
1,3 position (33.07 vs 4.93%) and PUFAs in the sn-2 position (9.57% vs 7.05%) instead of BM. 
Thus, both kind of samples show similar lipid profiles, but the most important difference was the 
stereospecific FAs distribution. Moreover, the levels of vegetables, fish, microalgae oil and raw 
materials were also measured in FM, to characterize in a better way its lipid composition [77]. 
A comparative approach was used by Quian and co-workers [78], comparing BM metabolic profile 
to FM and bovine milk.  Gas chromatography-time-of-flight mass spectrometry (GC-TOFMS) and 
ultra-performance liquid chromatography-quadrupole-time-of-flight mass spectrometry (UPLC-
QTOFMS) were performed. N=30 BM samples were obtained from n=30 lactating mothers. 
Moreover, n=20 bovine samples and n=20 FM samples were investigated.  
As result, BM, FM and bovine samples were clearly distinct. It was shown that BM was 
characterized by higher levels of non-esterified SFAs with aliphatic tails <16 carbons (potentially 
reflecting triglycerides’ hydrolysis), monounsaturated and PUFAs and lower levels of tricarboxylic 
acids (TCA) intermediates when compared with FM and bovine samples.     
Mostly varying metabolites belonged to the following classes: non-esterified fatty acids (NEFAs), 
free amino acids (FAAs), TCA intermediates, and free carbohydrates. 
NEFAs, including SFAs, MUFAs and PUFAs were more complex in BM samples.  Among the 
NEFAs, palmitic and stearic acid represented two exceptions, being lower in BM.  In each sample 
type, free amino acids and carbohydrates showed unique prophiles.  
In BM, higher of non-esterified myristoleic acid (14C:1), palmitoleic acid (16C:1), oleic acid (C18:1) 
and eicosenoic acid (C20:1), linoleic acid (C18:2) and alpha-linolenic acid (C18:3),  
eicosapentaenoic acid (C20:5), docosapentaenoic acid (C22:5) , docosahexaenoic acid (C22:6), 
gamma-linolenic acid (C18:3), eicosadienoic acid (C20:2), eicosatrienoic acid (C20:3), arachidonic 
acid (C20:4) and docosadienoic acid (C22:2) were detected. Moreover, a higher aboundance of 5-
oxoproline, alanine, arginine, glutamic acid, glutamine, glycine, serine, taurine, tyrosine, valine and 
fucose was pointed out. Lower levels of  phenylalanine, histidine and taurine, proline, TCA 










ketoglutaramic acid, cis-aconitic acid and malic acid characterized BM samples. In addition, BM 
was lower in arabinose, mannose, glucosamine and acetylglucosamine, fructose, maltose and 
threitol [78]. 
Another metabolic comparison between BM and bovine milk was performed by Liang and 
colleagues [79], using isobaric tags for relative and absolute quantification technology combined 
with liquid chromatography tandem mass spectrometry (iTRAQ technology combined with LC-MS 
detection). The authors measured the levels of free and hydrolytic amino acids in n=30 samples of 
BM collected from n=30 Chinese mothers between 7 and 14 days post-partum and compared them 
to n=30 bovine samples. 
As result, it was reported a total free amino acid content of 0.32 g/L in bovine milk and 0.63 g/L in 
BM and a content of total hydrolytic amino acids of 4.2 g/L and 2.2 g/L respectively. Moreover, 
amino acid content in BM was more abundant and highly varied.   
From metabolomics analysis, BM and bovine samples underwent a clear separation; N=42 amino 
acids were detected: n=27 showed higher levels in BM than bovine samples. 
Human BM samples resulted rich in histidine, leucine, lysine, phenylalanine, citrulline, 1-Methyl-L-
histidine, glutamic acid, glutamine, threonine, serine and glycine. 
Asparagine, aspartic acid and cysteine were exclusively detected in BM. Bovine samples 
contained high levels of isoleucine, leucine, valine, histidine, methionine, valine, threonine, 
arginine, tyrosine, γ-amino-butyric acid, taurine, α-aminobutyric acid, phenylalanine, ethanolamine 
and glycine [79]. 
By these studies, it can be concluded that BM, FM and bovine milk have their peculiar metabolic 
profile, which result unique for each milk type. Improving our knowledge on this topic, through 
metabolomics, will help to ameliorate commercial FM and dairy products composition, potentially 
resembling in the most accurate way BM components.  
A unique and recent preliminary investigation by our study group, compared metabolomics profiles 
of n=15 different kinds of FM (among these, n=6 organic –bio formulas) and BM (using 1H-NMR). 
Among the interesting obtained results, it emerged that methionine is significantly higher in organic 
–bio formulas (about 3 folds higher) than conventional FM [80]. It is interesting to underline that 
methionine is involved in methylation processes, fundamental in the establishment of epigenetic 
patterns.  
The recent findings of Odintsova et al., investigating methylation pathways in buccal cells of 
children, allows to conclude that breastfeeding, and potentially the metabolic composition of FM, 











6. BREASTFEEDING RELATED TO GROWTH 
 
BM metabolomic analysis can be also used to evaluate the effects of each component on neonatal 
and infantile outcome, with promising results. 
The effect of each mother’s BM lipidome was recently correlated to the growth pattern in a cohort 
of premature neonates [82]. N=26 preterm neonates born between 26-36 w of GA and fed with 
their mother’s BM were enrolled; among them, n=11 underwent a “faster” growth pattern while 
n=15 a “slower” growth.   
Samples were collected between 2 and 7 weeks of lactation. The evaluation of lipid species 
performed with LC-MS showed a clear separation between samples belonging to these different 
groups, especially in samples collected between 2 and 4 weeks of lactation.  
BM samples of infants belonging to the “faster” group contained more total fats (4.75 g/100 mL vs 
3.55 g/100 mL), medium-chain SFAs, sphingomyelin, dihomo-linolenic acid (DGLA)-containing 
phosphethanolamine, total SFAs (free and triglycerides- and phospholipid -bound FAs), medium-
chain SAT (MCSAT), n-3 long-chain PUFA, such as docosahexanoic acid, eicosapentaenoic and 
docosapentaenoic acids, medium- or long-chain sphingomyelins-SM and Cer [such as Cer 
(d18:1/24:0), SM(d18:0/12:0)], several phosphatidylcholines, phosphatidylethanolamines or 
plasmalogen-derivatives containing palmitic (C16:0) or palmitoleic (C16:1) acid [such as PE 
(16:0/16:1), PE (16:1/20:0)], stearic (C18:0) or oleic (C18:1) acid [such as PC (18:0/18:1), PC 
(18:0/18:2) and PE (O-18:0/20:5)], DGLA, C20:3, [PE (20:3/22:6), PE (22:0/20:3)], or 
docosahexaenoic acid (DHA, C22:6) [PE (20:3/22:6)].  
“Faster” sample contained less oleic acid, oleic acid-containing triglyceride and DGLA-oxylipin, 
total MUFAs, long-chain triglycerides (TG) containing oleic acid (C18:1) [such as TG 
(18:1/18:1/18:2), TG (16:0/17:1/18:1) and TG (18:0/18:1/18:1)], eicosanoids, including many 
DGLA-derived oxylipins [15S-HpEDE, 11-deoxy-16, 16-dimethyland 9-deoxy-9-methylene-16,16-
dimethyl-PGE2], Lyso-phospholipids (LysoPS) [LysoPS (22:0) and LysoPG (22:4)]. 
Among the n=162 lipids discriminating the two classes of samples, n=9 resulted the best predictors 
of neonatal weight growth. I.e., medium-chain sphingomyelin [SM (d18:0/12:0)], phospholipid 
containing DGLA and DHA [PE (20:3/22:6)], DGLA-derived oxylipin, TG-containing oleic acid (TG 
(16:0/17:1/18:1), TG (18:0/18:1/18:1)) and MCSAT, resulted strongly associated with neonatal 
growth, probably depending on their involvement in energy production, reduction of oxidative 
stress, modulation of gastrointestinal inflammation. Moreover, oxylipin is a bioactive component 
involved in neonatal metabolism and outcome [82].  
Through a successive study, the same authors globally evaluated metabolome, lipidome, glycome, 
FAs, and free amino acids in samples collected from the same cohort study (“faster” vs “slower” 











In BM collected from the “faster” growth group, higher levels of essential amino acid total content, 
especially branched-chain, insulinotrophic and gluconeogenic amino acids (BCAA), arginine and 
tyrosine, lacto-N-fucopentaose, choline, hydroxybutyrate, orotic acid, nicotinamide, hydroxybutyric 
acid, pyruvic and citraconic acids, were pointed out. 
Lower levels of glycine and taurine, glutamate, glutamine, sulfur amino acid content (taurine and 
methionine) cresol and benzoic acid were also detected.  
Regarding HMOs content, samples were adjunctively divided according to maternal Se+ (n=21) or 
Se- (n=5) status.  
In “faster” samples, higher levels of total fucosylated HMOs, especially LNFPI, di-fucosylated 
HMOs, an isomer of LNDFH and neutral HMOs such as lacto-N-hexaose (pLNH) were detected. 
On the contrary, neutral HMO 3000 and di-fucosylated HMO 4210b were lower.  
Some HMOs (LNFPI and 4210d, 4230b and 4230c) and amino acids (valine, glycine) seem 
predictive of a “slower” growth.  
LNFP I, LNDFH, 3’FL and pLNH were highly predictive only in Se+ mothers, while di-fucosylated 
HMOs (4230c, 4230b, 4240b, and 4210d) were predictors independently by Sectetor status.  
Regarding lipidomics, medium-chain saturated fatty acids (MCSAT such as pentadecanoic and 
myristic acid), TG (TG(46:0) and TG(50:2)), phospholipids (PS(38:4) and PE(38:3)) seem 
characterize the  “faster” group. 
On the contrary, oleic acid, plasmalogen-derivatives (PC(P-34:2) and PE(P-36:0)), lyso-
phosphatidylethanolamine-containing arachidonic acid (LysoPE(20:4)), Cer (Cer(18:1/22:0)) and 
very long-chain TG (TG(54:4) and TG(58:7)) seem indicate a “slower” growth. 
The most relevant metabolites predicting an optimal growth resulted:  arginine-creatinine pathway, 
aromatic amino acid metabolism, nicotinamide adenine dinucleotide precursors, sulfur metabolism, 
oligosaccharides,   mitochondrial fatty acid beta-oxidation, pyruvic, citraconic and aconitic acids, 
arginine, tyrosine, hydroxy-3-methylbutyric acid, undecenal, dodecanedioic acid and choline, 3-
hydroxycapric acid, dihydrocaffeic acid 3-O-glucuronide, LNFPII,  9-undecenal, heptanoyl- and 
hexanoyl-glycine, 3-hydroxy-adipic acid, valerenic acid. 
From these results, it can be deduced that BM samples in the “faster” growth group is more 
adequate to sustain preterm newborns’ development, containing more energy, more digestible 
calories for immature gastrointestinal system, a higher proportion of aminoacids promoting protein 
synthesis, bioactive molecules preventing NEC, promoting immune system development and 
improving neonatal outcome [83].  
The study of Cheatham and co-workers [84] investigated the potential correlation between some 
BM compounds (lutein, choline and DHA) and infant cognitive outcome (in detail, recognition 
memory abilities at six months of age measured by an electrophysiological assessment). 
The authors report data belonging to n=55 participants; BM samples were obtained between three 










choline and lutein levels, as well as the increase in  choline and DHA, resulted associated to better 
recognition memory. 
These nutrients, taken together, seem to act synergistically in the brain, sustaining the 
development of such organ and cognitive improvement [84].  
 
7. MICRONUTRIENTS LEVEL ASSESSMENT 
 
According to recent data, OMICS technologies seem able to investigate the effects and efficacy of 
micronutrients (MN) supplementation and dietary interventions, even in the periconceptional 
period.  
The average MN values in BM are related to maternal intake, even if it is not exactly known what 
level of maternal intake is adequate to satisfy neonatal needs [85]. The content of several Vitamins 
(such as Vitamin D, Vitamin A and water-soluble vitamins) reflects the diet of the mother. Breastfed 
infants of mothers following a strict vegan diet are at high risk of severe megaloblastic anemia and 
neurological deficit because of Vitamin B12 deficiency. The ESPGHAN recommends 
supplementation of breastfed infants or their breastfeeding mothers with Vitamin B12 if lactating 
mother follows a vegan diet [86].  
In this regard, according to Hampel and co-workers, UPLC-MS can perform the simultaneous 
determination of thiamin, riboflavin, niacin, vitamin B6, Vitamins A and E in BM; moreover, iron, 
copper and zinc can be measured through coupled plasma atomic emission spectroscopy [87,88].  
Through these technologies, it was pointed out a high variation on BM MN content among different 
mothers, especially belonging to different populations; moreover, values resulted lower than 
infants’ requirements. Metabolomics also provides information regarding the efficacy of 
supplementation; interestingly, the interference of some drugs with MN levels can be determined, 
such as the effects of antiretroviral drugs that can reduce some MN levels [89]. 
In detail, the study of Hampel and colleagues [87] aimed to determine if a reduced maternal intake 
of B-vitamins during lactation could determine infant deficiency, with potential clinical 
manifestations.  
UPLC–MS was used to detect thiamin, riboflavin, flavin adenine dinucleotide (FAD), nicotinamide 
and pyridoxal (PL) on n=80 BM samples collected from mothers living in Cameroon, China, India, 
Malawi and the USA during the first month of lactation.  
It was shown that thiamin, niacin and B-6 levels increased during lactation. Significant differences 
occurred depending on geographic origins, especially regarding vitamin B-2 and niacin.  
The USA samples showed significantly higher levels of nicotinamide. Pyridoxal was significantly 
lower in samples from Malawi and USA. High levels of thiamin in the Cameroon samples might 










related to differences in diet and fortification. Since the samples were collected at different lactation 
stages, the influence of such variability on vitamin level should be taken into account [87].  
 
8. BREAST MILK CONTAMINANTS 
 
The presence of contaminants in BM can influence neonatal outcome. According to recent data, 
metabolomics represents a promising tool to explore the levels of such contaminants and define 
BM safety. 
Persistent organic pollutants (POPs), such as organochlorine pesticides (OCPs), organophosphate 
pesticides (OPPs), polychlorinated biphenyls (PCBs) and polychlorinated dibenzo-p-dioxins 
(dioxins), are synthetic environmental chemicals which can be absorbed by inhalation, ingestion or 
dermal contact by lactating mothers and potentially excreted in BM. Even if the exact mechanism is 
not fully exploited, they can interfere with endocrine systems and impair neonatal 
neurodevelopment. Du and colleagues [90] performed the first longitudinal study investigating 
pesticides’ concentration in BM, its modifications during the first year of lactation and neonatal daily 
pesticides’ intake. These values have been analyzed together with infants’ growth outcome and 
maternal characteristics.  
N = 99 BM samples were collected from n=16 mothers living in Western Australia at 2, 5, 9 and 12 
months of lactation and the levels of 88 pesticides were analyzed with GC-MS/MS. Among these, 
only n=3 (3.4%) were detected: p,p’-dichlorodiphenyldichloroethylene (p,p’-DDE), p,p’-
dichlorodiphenyltrichloroethane (p,p’-DDT) and beta-Hexachlorocyclohexane (β-HCH). P,p’-DDE, 
the most abundant, was detected in n=83 samples (83%) and showed a mean concentration of 
52.25 ± 49.88 ng/g fat, p,p’-DDT 27.67 ± 20.96 ng/g fat and β-HCH 48.00 ± 22.46 ng/g fat. These 
concentrations significantly decreased along the first year of lactation.  
P,p’-DDE was not significantly correlated with infant growth outcomes and finally, neonatal daily 
DDTs intake was 14–1000 times lower than the threshold reference values and decreased 
significantly throughout the first 12 months of lactation [90].  
In a subsequent study, the same group investigated pesticide concentrations in a higher group of 
West Australian mothers (n=40) at the same lactation points (2, 5, 9 or 12 months), through GC-
MS [91]. P,p’-DDE was detected at trace levels, showing a mean concentration of 62.8 ± 54.5 ng/g. 
It did not result associated with infant growth outcomes such as weight, length, head circumference 
and percentage fat mass. Moreover, breastfed infant daily intake resulted at least 59 fold below the 
tolerable daily intake (TDI) recommendations [91].  
Another group validated HPLC coupled to electrospray mass spectrometry (HPLC-ESI-MS) to 
detect BM levels of selective serotonin reuptake inhibitors-SSRI (citalopram, fluoxetine, 
fluvoxamine, paroxetine and sertraline and their major metabolites desmethylcitalopram and 










and continuing drug administration during lactation, these drugs may pass through breastfeeding 
and negatively affect neonatal outcome.  
This innovative analytical method could allow the simultaneous detection of all SSRI drugs and 
their metabolites. From each SSRI-treated mothers, n=2 BM samples were collected during the 1st 
and/or 4th w postpartum.  
After the detection of BM SSRI levels, the relative infant circulating dose (RID) can be obtained, to 
predict the possible occurrence of adverse effects (generally not expected if RID is lower than 
10%), except in newborns at higher risk of drug accumulation or exposed to multiple drugs. 
Although this is an ongoing study and complete results will be published in the next future, RID 
ranges between 0.5% and 9% have been reported [92].  
An interesting study investigating BM contaminants was performed by Braun and co-workers [93]. 
Mycotoxins, secondary metabolites produced by several moulds, including Aspergillus, Fusarium 
and Penicillium species may contaminate many agricultural products.  
The most common mycotoxins are aflatoxins (AFs), fumonisins (FBs), ochratoxin A (OTA), 
zearalenone (ZEN) and trichothecenes. Among the side effects of these substances, a correlation 
with neural tube defects, stunting, esophageal cancer, breast cancer and kidney toxicity was 
reported. Moreover, they act as endocrine disruptor.  
Since the possible transfer to breastfed infant, it must be also underlined that early mycotoxins 
exposure during the first phases of life can impair short- and long-term outcomes and should be 
limited in this vulnerable period.   
LC-MS/MS has been applied to analyze n=75 BM samples from n=22 Nigerian mothers, assessing 
the levels of 28 mycotoxins (including aflatoxins, ochratoxin A, deoxynivalenol, zearalenone) and 
their metabolites.  
As result, it was observed that many samples were not contaminated or minimally contaminated 
with beauvericin (56%), enniatins B (9%), OTA (15%) and aflatoxin M1 (1%). Beauvericin, not 
previously reported, was the most abundant (up to 0.019 ng/mL). It can be concluded that tolerable 
daily intakes have not b en exceeded but further studies are needed on this topic [93].  
A recent field of metabolomics application is the analysis of adulterants in BM, potentially occurring 
in the recently popular market of such biofluid.  
Soy, almond, cow, goat milk and infant formula could be added to dilute BM. This could not be so 
safe and a method to detect contaminants would be needed. In a recent study, a high performance 
chemical isotope labeling (CIL) LC-MS platform was applied to analyze the metabolome of an 
unknown milk sample, comparing it to human BM (N=10 samples of BM were collected at various 
lactation times) [94]. According to the similitude, the authors differentiated the six different kind of 
samples as follows. N=1043 metabolites were detected in BM, n=2925 metabolites in goat milk 
(among these, n=834 in common with BM), n=2670 in cow milk (n=851 in common with BM), 










BM), n=1553 in FM (n=518 in common with BM). The results of this study show that although in the 
amine/phenol metabolomes of human, soy, almond, cow, goat and infant FM there are many 
common metabolites, there is a large number of unique metabolites specific for each kind of milk. 
Thus, this method is able to detect metabolomic differences between non-adulterated BM and BM 
containing 5% or more potential milk adulterant and could be also applied to other fluids [94].  
In a recent interesting study, BM environmental chemical toxicants have been measured and 
correlated to modifications in neonatal gut microbiome at 1 month of life [95]; BM samples from 
n=267 Norwegian mothers were collected each morning for eight consecutive days, between 2 
weeks and 2 months postpartum and n=28 chemical exposures were measured.  
Liquid-liquid extraction and GC-MS and high-performance LC-MS were used. 
It was reported that environmental toxicants in BM, notably polybrominated flame retardants 
(especially PBDE-28), Perfluorooctanoic acid (PFOA), surfactant perfluorooctanesulfonic acid 
(PFOS), and dioxin-like polychlorinated biphenyls (especially PCB-167), are associated with less 
microbiome diversity and negatively influence infant gut microbial composition during the critical 
neonatal period [95].  
 
9. METABOLIC EFFECTS OF DIFFERENT NEONATAL NUTRITION STRATEGIES 
 
Metabolomic differences occurring in neonates fed with BM and FM can be investigated through 
urine, feces and blood samples, as recently reviewed by Phan et al. [96].  
The obtained results pointed out the importance of metabolomics in the evaluation of neonatal diet, 
pointing out the differences occurring between BM and FM fed subjects, the potential metabolic 
implications of a nutritional deficiency, therefore helping in the improvement of FM composition. 
 
9.1 Serum metabolome according to neonatal nutrition  
 
From a recent study, it can be stated that lipid biomarkers in neonatal serum (detected through 
infusion high-resolution mass spectrometry) could be useful to understand neonatal nutrition 
regimen, differentiating BM fed from FM fed infants at 3-6 months of age.  Lipidomic profiles 
compared between the two groups pointed out the presence of phosphatidylcholine PC(35:2), and 
two sphingomyelins SM(36:2) and SM(39:1), whose variations seems to correlate to the different 
nutrition pattern [97].  
 
9.2 Urinary metabolome according to neonatal nutrition  
 
Several studies applied metabolomics analysis to neonatal urine to evaluate the effects associated 










In the study of Cesare-Marincola et al. [98], urinary metabolome of BM neonates was compared to 
urine samples of subjects fed with two different kind of FM. In the three groups, urinary 
metabolome changes were mostly influenced by infant growth than the dietary regimen. Similar 
temporal trends of choline, betaine, myo-inositol, taurine, and citrate levels occurred. Some 
differences characterized metabolic profile of breastfed neonates, while variations were not 
detected between subjects fed with the two types of FM. In detail, a two-fold increase 
characterized the levels of citric acid and fucosyl- compounds in infants fed with BM. In neonates 
fed with FM, a two-fold increase characterized pantothenic acid, while a three-fold increase was 
observed in tartaric acid levels, compared by box-whisker plot analysis [98].  
Moreover, another study evaluated urinary metabolomics according to neonatal nutrition in the 
following groups: intrauterine growth restriction (IUGR), LGA, and AGA neonates. Through GC-
MS, interesting findings were pointed out. In fact, at birth, IUGR and LGA neonates’ metabolome 
was different from that of AGA. However, after three days of alimentation, metabolome variation 
was dependent on nutritional regimen. In detail, higher levels of glucose, galactose, glycine, myo-
inositol, aconitic acid, aminomalonic acid and adipic acid were detected in BM fed neonates [99]. 
The role of neonatal nutrition on urinary metabolome was also confirmed in a recent study 
detecting lower levels of 8-hydroxy-20-deoxyguanosine, a marker of oxidative DNA damage, 
choline, choline metabolites, lactic acid, PGD2 and markers of insulin sensitivity in BM fed 
neonates than FM. On the contrary, surprisingly, atherosclerotic indices were significantly higher in 
breastfed neonates [100]. 
 
9.3 Fecal metabolome according to neonatal nutrition  
 
Three recent studies applied metabolomics to detect fecal changes according to neonatal nutrition. 
Chow and co-workers [101], through GC-MS and LC-MS on fecal samples, detected higher levels 
of n=14 compounds including HMOs, linoelaidate and myo-inositol in neonates assuming BM 
(n=4); on the contrary, in the stools of neonates assuming FM (n=4), higher levels of n=41 
metabolites can be considered indicators of carbon limitation and protein fermentation [101].   
In the trial of Liu et al. [102], subjects from 7 to 90 days of postnatal life were enrolled and fed with 
BM or two different kind of FM. Metabolomic results obtained from fecal analysis evidenced higher 
levels of Bifidobacteria spp. and acetic acid in breastfed neonates and in those fed with Synlait 
Pure Canterbury Stage 1 infant formula (SPCF).   
Thus, fecal bacterial composition and SCFAs were comparable in subjects fed with BM and SPCF, 
contrarily with what reported in rats [102].  
Finally, Bazanella and co-workers [103] aimed to evaluate metabolic changes in stools of infants 











In subjects belonging to the 3rd group, lower levels of Bacteroides spp. and Blautia spp. and 
variations in lipids and unknown metabolites levels were detected. At 1 month, significant 
differences were also evident between BM an FM fed subjects [103].   
Thus, fecal metabolomics could improve our knowledge regarding the interaction occurring among 
diet, intestinal microbiome and the host.  
 
10. RECENT PROGRESSES  
 
Due to the complex composition of BM, metabolomic sample analysis requires complexes 
extraction methods and analytical platforms. New methods are constantly introduced and 
innovations in metabolomics contribute to improve sensibility of these techniques and accuracy of 
results. 
In example, liquid-liquid extraction (LLE) and solid-phase extraction (SPE) techniques have been 
combined to perform a semiquantitative analysis of lipids through LC-MS. Thus, an 
extensive dynamic metabolome coverage, especially for low-abundance glycerophospholipids and 
sphingolipids, was obtained [104].  
Moreover, a novel method to analyze TG fraction in BM samples has been recently applied; Liquid 
Extraction Surface Analysis coupled to Fourier Transform Mass Spectrometry (LESA‐MS) allowed 
molecular profiling. The technique based on Collision‐Induced Dissociation (CID) was recently 
used to profile fatty acid residues. Thus, the presence of very long chain fatty acids (C26:0 and 
C26:1), not previously reported, has been detected [105].  
Lipids constitute about 5% of BM. Since its important role in infant nutrition, their characterization is 
very useful; however, lipid fraction is highly variable; thus, analysis and standardization is difficult. 
The introduction of new chromatographic techniques, such as liquid and supercritical fluid 
chromatography, as well as mass spectrometry, allow a better characterization of BM lipidome 
[106].   
According to another study, the Biocrates AbsoluteIDQR p180 kit for human milk metabolomics 
(detecting 40 acylcarnitines, 42 acids/biogenic amines, 91 phospholipids, 15 sphingolipids) can be 
used for human BM analysis and plasma evaluation, providing comparable and homogeneous 
results [107].  
Regarding next future progresses, the paper of Minegishi et al. describes the importance of the 
innovative Tohoku Medical Megabank biobank (TMM biobank), representing the first major 
population-based biobank in Japan. In this structure, there are 3.4 million tubes of biospecimens 
and associated health and analytic data belonging to about 150,000 TMM cohort participants. 
Samples include peripheral and cord blood mononuclear cells, buffy coat, plasma, serum, urine, 
breast milk and saliva and are indispensable for academic, clinical and industrial research even for 










11. PASTEURIZATION EFFECTS 
 
Donor human milk (DM) could be very useful for neonates whose mother can not supply with their 
own milk.  
Serveral treatments can be performed to ensure BM microbiological safety, even if they can affect 
its composition and impair nutritional or biological properties. 
Holder pasteurization is the process currently recommended in Human Milk Banks (HMBs); in 
NUCUs, BM freezing is also common.  
Both act on BM oxidative stress [109].   
The effects of pasteurization and cold storage on BM has been investigated through several 
studies, evidencing different levels of BM alteration [110-112].  
Many data also report the beneficial effects of DM on preterm infants.  
The effects of pasteurization and refrigeration on oxidative stress and biological BM properties 
should be further evaluated and metabolomics could help to describe accurately such processes 




Metabolomic analysis of BM is currently a topic of great interest and several studies have been 
performed in the last years, to evaluate and describe the fluid more recommended for neonatal 
nutrition. 
Such OMICS technology, not invasively performed, allows a detailed description of BM 
components, investigating their dependence on maternal or environmental factors, perinatal events 
and neonatal characteristics; moreover, the possible roles of each component and potentially 
related neonatal and infantile outcomes can be investigated.  
Highly interesting is the possible detection of BM changes during lactation, understanding its 
modification according to neonatal requests during growth and development.  
The dependence of BM composition according to GA at birth allows the description of BM 
modifications in mothers delivering preterm neonates, producing BM susceptible to higher 
variability, or, as recently reported by our research group, in mothers delivering multiples. Maternal 
factors affecting BM composition including genetics, geographical proveniences, diet, delivery 
mode or diseases such as gestational diabetes mellitus or mastitis can be also evaluated through 
metabolomics. 
Metabolic evaluation is also helpful in describing the effects of BM components on gut microbiome 
of breastfed infant, detecting the interplays occurring between milk metabolites, gut bacteria and 










A clear and well defined correlation between each metabolite and its health outcome is not 
currently available; however, we are working at the creation of specific atlas dealing with 
metabolites and their involvement in several diseases and conditions, in pediatrics and especially 
in neonatology [113]. 
Moreover, metabolomics also results useful to investigate BM micronutrients levels (to highlight the 
necessity of supplementation), the level of contaminants and pesticides (to attest BM safety for 
breastfed neonates) and is also able to detect the levels of maternal drugs potentially transferred 
with breastfeeding.  
The effects of several treatments on milk samples (including pasteurization or freezing), to 
investigate potential impairment of BM or FM potentialities, can be also performed through a 
metabolomics approach.  
Improving all this knowledge will provide a global picture of how BM components interacts and how 
they change across lactation, to sustain neonatal growth and improve short- long-term outcomes.  
In detail, growth outcomes and neurodevelopment seem highly correlated with BM melabolome. 
Moreover, a deeper description of BM composition will enable the production of FM more 
appropriate as possible for each neonate, i.e. through the supplementation with metabolites, 
probiotics, prebiotics or more. 
More biofluids can be contemporarily investigated (i.e. BM and neonatal biofluids), to investigate 
potential direct effects of nutrition on neonatal metabolome. 
Due to the extraordinary inter-individual variability, each neonate or infant is unique. A central point 
in personalized nutrition could be the tailoring on each person, influencing neonatal outcome, also 
taking into account the effects played by BM on neonatal gut microbiome.  
Since a single metabolomics platform is not sufficient to globally describe each constituents of a 
biofluid, several studies underline the importance of an integrated approach based on the 
combination of several techniques; a great number of studies underline the importance of new 
approaches or more innovative techniques to improve the accuracy of BM analysis. 
 
13. EXPERT OPINION:  
 
Due to the great progresses of medical research and the interesting results published in the last 
years, we ought that the next future could be based on a “personalized” and “tailored” nutrition, 
according to each subjects’ needs. In this direction, metabolomics is giving fundamental 
opportunities, representing a versatile tool in several fields of medicine, including neonatal nutrition 
and breastfeeding. 
By an accurate analysis of all the available studies, it is now clear that each neonate can not be 
analyzed individually, being part of a complex dyad in which he is closely connected to his mother. 










biofluids or tissues representing a direct interface between mother and newborn, such as placenta, 
umbilical cord, amniotic fluid or breast milk, whose function has been compared since ancient 
times to maternal blood, providing to the neonate nutrients but also bioactive components and 
cellular elements even after birth. 
In this review, we analyzed in depth the potential application of metabolomics analysis to maternal 
BM, in relation to several maternal, perinatal, neonatal or environmental conditions.  
In addition, we underline that BM evaluation should be put in relation with the analysis of other 
neonatal fluids, such as urines, feces or blood, to directly investigate metabolic pathways related to 
different metabolites in BM of FM and therefor triggered by different kinds of neonatal nutrition. 
Taking into account the concept of mother-child dyad, relevant information could also be obtained 
by the analysis of maternal biofluids, due to the high influence of maternal factors on BM 
constituents.  
It is now clear that one of metabolomics goals would be an easy integration of several analytic 
platforms, providing a detailed and complete description of the analyzed samples, even if the high 
costs of such techniques and the needs of highly specialized operators could represent a great 
limitation in the diffusion of such methods.  
In the microbiomics era, it is widely known that metabolomics is a fundamental instrument, able to 
detect the effects of metabolites on microbiome composition, such as BM metabolites effects on 
maternal “lactobiome” and on neonatal gut microbiome, representing the linking ring among 
microbial communities and the interactions occurring with the host.  
We ought to underline that despite the numerous studies reported in the field, many efforts are still 
needed to obtain a better standardization of the population studied and the samples collected and, 
primarily, many studies are required to identify all the possible clinical effects and implications of 
detected metabolites. 
If the entity and the meaning of each metabolite variation should be clarified in a direct and 
univocal way, the results obtained through metabolomics analysis would provide reliable, 
reproducible, standardiz d and safe data in each clinical setting, allowing the pediatrician or 
neonatologist to orient his clinical and therapeutic practice according to metabolic findings. 
To further simplify such process, the use of less complex platforms would be desirable. In our 
opinion, in five or ten years, several progresses could be obtained in this direction. The ideal 
strategy, could be the introduction of metabolomics sticks, potentially accurate and cheap, to 
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and uridine. Chinese 
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Finland: higher LNFP I. 
Spain: higher 2’FL, 
SCFA, acetate and 
formate. South Africa: 
higher 3’FL. LDL and 
VLDL higher in Spain 
and Finland. In vaginal 
delivery: higher 3-
hydroxybutyrate and 
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Se-: more α1,3/4-linked 
fucosyl-
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fucose linked only by 
α1,3 or α1,4 glycosidic 
bonds (while α1,2 
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were lacking); Se+ 
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according to  GA, BW, 
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higher malic acid, 
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BM:  higher amino acids 
(threonine, valine, 
alanine, serine, glutamic 
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FM: lower SFAs, higher 
UFAs (38.20% vs 
30.59%) and  
comparable PUFAs 
(9.92% vs 17.96%). 






















SFAs esterified mainly 
in the sn-1,3 position 
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PUFAs in the sn-2 
position (9.57% vs 
7.05%) than BM. BM: 
higher of SFAs in the sn-
2 position (26.03% vs 
2.93%) and PUFAs in 
the sn-1,3 position 
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FAAs, TCA, free 
carbohydrates 
BM, FM and 
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their peculiar 
metabolic profile, 
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BM maturation 
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detected: n=15 sugars, 
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energy-related 
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n=3 nucleotides, n=2 
vitamins, and n=5 
BM metabolites 
vary during the 
first month of 
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highest variability 
















28)  bacterial metabolites. 
Colostrum and MM 




Most HMOs decreased. 
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higher total and neutral 
HMOs, 2’-FL, 3’-GSL, 
3’-SL, 6’-SL, fucose, 







pyruvate, hyppurate and 
methanol. Pre-term MM: 
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Metabolic differences in 
colostrum, TM and MM. 
Full-term colostrum: 
higher valine, leucine, 
betaine, and creatinine 
instead  MM. 
Full-term MM: higher 
glutamate, caprylate and 
caprate than colostrum. 
Pre-term colostrum: 
higher HMOs, citrate 
and creatinine.  
MM: Higher caprylate, 
caprate, valine, leucine, 
butyrate, alanine, 
glutamate, pantothenate 
3-FL, LNDFH I and 
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by an increase in lactose, 
choline, alanine, 
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butyrate and formate 
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BM and bovine samples 
underwent a clear 
separation. Total free 
amino acids: 0.32 g/L in 
bovine milk and 0.63 g/L 
in BM. Total hydrolytic 
amino acids of 4.2 g/L 
and 2.2 g/L respectively. 
N=42 amino acids 
detected: n=27 higher in 
BM than bovine 
samples. 




glutamic acid, glutamine, 
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glycine. Asparagine, 
aspartic acid and 
cysteine exclusively in 
BM. Bovine samples: 
higher isoleucine, 
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The two categories 
characterized by two 
different metabolic 
profiles. 
 Pre-term samples: 
higher lactose (4.46 
ppm) and HMOs, 
especially fucosylated, 
such as fucose (1.23 
ppm), N-acetyl-
neuraminic acid (2.06 
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QTOFMS measured in three 
lactation phases: n=12 
fatty acyls, n=15 
glycerolipids, n=23 
glycerophospholipids, 
n=7 sphingolipids, n=7 
vitamins, n=5 
nucleotides, n=2 amino 
acids, n=1 amino acid 
metabolites, n=9 
dipeptides, n=1 steroid 
hormones, n=1 energy-
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n=1 amine. 
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BM analyzed for 
macronutrients and FAs. 
Serum phospholipids, 
acylcarnitines, and 
amino acids LPC 
correlates with BM FAs 
and protein content, 
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omega-3 Fas was not 
significantly correlated 
with BM content, while 
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compounds belonging 
LOX and COX 
pathways, such as 
resolvins, protectins, 
maresins, lipoxins and 
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In mastitis: higher 
proinflammatory 
mediators (LTB4 and 
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A synergistic increase in 
choline and lutein levels, 
as well as the increase in  
choline and DHA, 
associated to better 
recognition memory 
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HMO 4210b, glycine, 
taurine, glutamate, 
glutamine, taurine, 
methionine, cresol and 
benzoic acid. 
“slower” growth: higher 
LNFPI and 4210d, 
4230b and 4230c, valine 
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pLNH highly predictive 
only in Se+ mothers, di-
fucosylated HMOs 
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P,p’-DDE the most 
abundant, detected in 83 
samples (83%). Mean 
concentration 52.25 ± 
49.88 ng/g fat. 
P,p’-DDT 27.67 ± 20.96 
ng/g fat. 
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Many samples not 
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minimally contaminated 
with beauvericin (56%), 
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enniatins B (9%), 
ochratoxin A (15%) and 
aflatoxin M1 (1%). 
Beauvericin the most 
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e CIL  
LC-MS 
N=1043 metabolites 
detected in BM, n=2925 
in goat milk (among 
these, n=834 in common 
with BM), n=2670 in 
cow milk (n=851 in 
common with BM), 
n=1348 in almond milk 
(n=488 in common with 
BM), n=2562 in soy 
milk (n=583 in common 
with BM), n=1553 in 
FM (n=518 in common 








































PFOS and dioxin-like 
polychlorinated 
biphenyls (especially 











Table 1. Summary of metabolomic studies on human breast milk (BM). Update of the review of Cesare-Marincola et al [34]. 
1H-NMR=nuclear magnetic resonance spectroscopy; 2’FL=2’fucosyllactose; 3’FL=3’fucosyllactose; 3’SL= 3’ sialyllactose; 6’ SL= 6’ sialyllactose; 
β-HCH= beta-Hexachlorocyclohexane; AGA=appropriate for GA; AMP= adenosine monophosphate; AKI=acute kidney injury; BM=breast milk; 
BW=birth weight; CE-MS=capillary electrophoresis‐mass spectrometry; CIL=chemical isotope labeling; COX=cyclooxygenase; d=days; 
DGLA=dihomo-linolenic acid; DHA=docosahexaenoic acid; DHEA=Docosahexaenoylglycerol; dUMP=deoxyuridine monophosphate; FAs= fatty 
acids; FAAs=free amino acids; FM= formula milk; FAD=flavin-adenine dinucleotide; GA=gestational age; GC-MS= gas chromatography mass 
spectrometry; GC-TOFMS=Gas chromatography-time-of-flight mass spectrometry; GDM=gestational diabetes mellitus; HD=hemodyalisis; 
HMOs=human milk holigosaccharides; HPLC=high-performance liquid chromatography; HPLC-MS= high-performance liquid chromatography-
mass spectrometry; HPLC-QTOFMS=high-performance liquid chromatography–quadrupole-time of flight mass spectrometry; HPLC-ESI-MS=HPLC 
coupled to electrospray mass spectrometry; iTRAQ=isobaric tags for relative and absolute quantification technology; LC-MM=mature milk; 
MS=liquid chromatography tandem mass spectrometry; LDL= low density lipoproteins; LGA=large for GA; LNDFH=Lacto-N-difucosyl-hexaose;  
LNFP=lacto-N-fucopentaose; LnNT= Lacto-N-neotetraose; LOX=lipoxygenase; LPC=Lyso-phosphatidylcholine; LTB4=Leukotriene B4; 
LyPS=Lyso-phospholipids; MUFAs=monounsaturated fatty acids; NEFAs=non-esterified fatty acids; P,p’-DDE=p,p’-
dichlorodiphenyldichloroethylene; P,p’-DDT=p,p’-dichlorodiphenyltrichloroethane; pLNH=lacto-N-hexaose; PFOA=Perfluorooctanoic acid; 
PFOS=surfactant perfluorooctanesulfonic acid; 
PUFAs=polyunsaturated fatty acids; RID=relative infant circulating dose; SCFAs= short chain fatty acids; Se+=secretors; Se-=non secretors; 
SFAs=saturated fatty acids; SGA=small for GA; SSRI=selective serotonin reuptake inhibitors; SPM=pro-resolving mediators involved in host 
defense; TCA=tricarboxylic acid; TG=triglycerides; TM= transition milk; UFAs=unsaturated fatty acids; UPLC-MS=ultra-performance liquid mass 
spectrometry; UPLC-QTOFMS=ultra-performance liquid chromatography-quadrupole-time-of- flight mass spectrometry; VLDL= very low density 
lipoproteins; w=weeks 
  
 
  
 
 
 
